Abstract
Necrotizing enterocolitis is a life-threatening condition in preterm neonates that is associated with severe morbidity and mortality. Several studies have suggested that probiotics can potentially decrease the risk of developing necrotizing enterocolitis via several proposed mechanisms of action, including increasing diversity of the intestinal flora. However, due to a lack of standardized study designs, including variability in product selection, dose, time of initiation, and duration, as well as a concern for safety in this vulnerable population, the use of probiotics in this population remains controversial. Regulations for testing of products and well-validated dosing regimens are needed before considering routine use of probiotics in these high-risk patients.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
